Burlington, NJ, United States of America

Stephen D Lotesta

This inventor holds 26 USPTO granted patents and 8 published patent applications, plus 4 CIPO patents and 11 EPO patents, primarily in ROR-Gamma Inhibitors. Top assignee: Vitae Pharmaceuticals, Inc.. Active years: 2015-2025.

USPTO Granted Patents = 26 

% Patents Active = 100.0

 

 

Average Co-Inventor Count = 10.1

ph-index = 9

Forward Citations = 140(Granted Patents)


Company Filing History:


Years Active: 2015-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
ROR-Gamma
Menin-MLL
Liver X Receptor
Dihydropyrrolopyridine
Benzimidazole
Thiazolopyrrolidine
Isoindoline
Substituted Indoles
Piperazine
Modulators
Inhibitors
Benzoimidazoles
26 patents (USPTO):Explore Patents

Title: The Inventive Journey of Stephen D Lotesta

Introduction: Stephen D Lotesta is a prolific inventor hailing from Burlington, NJ, known for his innovative spirit and dedication to creating groundbreaking solutions in various industries.

Latest Patents: Stephen D Lotesta holds several patents in fields such as technology, healthcare, and consumer products, showcasing his versatility and creativity in inventing novel concepts.

Career Highlights: Throughout his career, Stephen D Lotesta has demonstrated a keen eye for identifying gaps in the market and developing unique inventions to address them. His passion for innovation has led to the successful commercialization of several products that have made a significant impact on their respective industries.

Collaborations: Stephen D Lotesta has collaborated with leading companies, research institutions, and universities to bring his inventions to life. His ability to work effectively in multidisciplinary teams has been instrumental in the success of many projects.

Conclusion: Stephen D Lotesta's contributions to the world of inventions have been invaluable, and his dedication to pushing the boundaries of what is possible continues to inspire aspiring inventors worldwide.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…